BioSpace News Archive

Median Technologies announces that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology, being held in Vienna, Austria, February 28 – March 3, 2024.

AB Science SA (Euronext - FR0010557264 - AB) today announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) regarding its New Drug Submission (NDS) for masitinib in the treatment of amyotrophic lateral sclerosis (ALS).

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY) today reported financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on recent developments.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced the successful amendment of its credit and security agreement with MidCap Financial Trust effective February 20, 2024.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for next-generation sequencing (NGS) library preparation and the Company’s EvoT4™ DNA ligase.

GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management will participate in the Cowen Healthcare Conference from March 4-6 in Boston, MA.

Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats.

Xtant Medical Holdings, Inc. (NYSE American: XTNT) today announced that Sean Browne, Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference, to be held on Monday, March 4, 2024 at 12:50 p.m. Eastern Time in Boston.

Revolution Medicines, Inc., a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, announced its financial results for the quarter and full year ended December 31, 2023, and provided an update on corporate progress.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the U.S. Food and Drug Administration (FDA) approved a new, expanded indication for Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, a common form of treatment resistance.